A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

NCT05485974 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Non Small Cell Lung Cancer
Colorectal Cancer
Cancer of Pancreas
Colon Cancer
Solid Tumor
Cancer

Interventions

DRUG: HBI-2438

Sponsor

HUYABIO International, LLC.